Insurance type is associated with appropriate use of surgical and adjuvant care for differentiated thyroid carcinoma

xlomafota13 shared this article with you from Inoreader Insurance type is associated with appropriate use of surgical and adjuvant care for differentiated thyroid carcinoma Via radioactive iodine Surgery. 2021 Sep 30:S0039-6060(21)00794-7. doi: 10.1016/j.surg.2021.07.038. Online ahead of print. ABSTRACT BACKGROUND: We aimed to characterize the association between differentiated thyroid cancer (DTC) patient insurance status and appropriateness of therapy (AOT) regarding extent of thyroidectomy and radioactive iodine (RAI) treatment. METHODS: The National Cancer Database was queried for DTC patients diagnosed between 2010 and 2016. Adjusted odds ratios (AOR) for AOT, as defined by the American Thyroid Association guidelines, and hazard ratios (HR) for overall survival (OS) were calculated. A difference-in-differences (DD) analysis examined the association of Medicaid expansion with outcomes for low-income patients aged <65. RESULTS: A total of 224,500 patients were included. Medicaid and uninsured patients were at increased risk of undergoing inappropriate therapy, including inappropriate lobectomy (Medicaid 1.36, 95% confidence interval [CI]: 1.21-1.54; uninsured 1.30, 95% CI: 1.05-1.60), and under-treatment with RAI (Medicaid 1.20, 95% CI: 1.14-1.26; uninsured 1.44, 95% CI: 1.33-1.55). Inappropriate lobectomy (HR 2.0, 95% CI: 1.7-2.3, P < .001) and under-treatment with RAI (HR 2.3, 95% CI: 2.2-2.5, P < .001) were independently associated with decreased survival, while appropriate surgical resection (HR 0.3, 95% CI: 0.3-0.3, P < .001) was associated with improved odds of survival; the model controlled for all relevant clinico-pat hologic variables. No difference in AOT was observed in Medicaid expansion versus non-expansion states with respect to surgery or adjuvant RAI therapy. CONCLUSION: Medicaid and uninsured patients are at significantly increased odds of receiving inappropriate treatment for DTC; both groups are at a survival disadvantage compared with Medicare and those privately insured. PMID:34600741 | DOI:10.1016/j.surg.2021.07.038 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Days alive and out of hospital following transoral robotic surgery: Cohort study of 262 patients with head and neck cancer

xlomafota13 shared this article with you from Inoreader Days alive and out of hospital following transoral robotic surgery: Cohort study of 262 patients with head and neck cancer Via Head & Neck Abstract Background Days alive and out of hospital (DAOH) is a validated outcome in clinical trials, since it reflects procedure-associated morbidity and mortality. Transoral robotic surgery (TORS) has become a widely adopted procedure with increasing demand for knowledge and data on morbidity. Methods Retrospective single-center assessment of a prospective TORS database comprising patients treated for malignancy between 2013 and 2018 using DAOH to describe procedure- and disease-related morbidity the first 12-postoperative months. Results For 262 patients, median DAOH365 was 357 days (IQR 351–360). Indications for TORS were (i) primary curative resection (61%), (ii) salvage resection (15%), and (iii) diagnostic work-up of cancer of unknown primary in the head and neck (24%). Median DAOH365 was 359 days (IQR 351–361 days), 348 days (IQR 233–355), and 357 days (351–361), respectively. Pneumonia had the highest impact in DAOH365 reduction. Conclusion Total median DAOH365 after TORS was 357 days. The main cause leading to DAOH365 reduction was pneumonia. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Massive Cervical Lymphadenopathy Post-COVID-19 Vaccination

xlomafota13 shared this article with you from Inoreader Massive Cervical Lymphadenopathy Post-COVID-19 Vaccination Via ear nose throat Ear Nose Throat J. 2021 Oct 2:1455613211048984. doi: 10.1177/01455613211048984. Online ahead of print. ABSTRACT The coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2. Rapid spread with rampant growth of cases and deaths brought forth an urgent need for novel therapies including vaccinations. The mRNA vaccines for COVID-19 disease have been implemented at an unprecedented scale in an effort to combat the unrelen ting pandemic. Such a massive scale vaccination program is bound to coincide with adverse events related to treatment. We present a case of massive cervical lymphadenopathy in a 58-year-old male patient post-Moderna COVID-19 vaccination. Additional investigations did not identify malignancy and he was diagnosed with vaccine-related lymphadenopathy. Patient significantly improved with corticosteroid treatment within 2 days of admission. Lymphadenopathy is reported as the second most common local reaction to the Moderna vaccine. Promoting knowledge of this side effect, particularly in the setting widespread vaccination efforts, would allow for better management of cases, especially in relation to oncologic patients. PMID:34601889 | DOI:10.1177/01455613211048984 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Solitary neurofibroma in the external auditory canal

xlomafota13 shared this article with you from Inoreader Solitary neurofibroma in the external auditory canal Via ear nose throat Ear Nose Throat J. 2021 Oct 2:1455613211048978. doi: 10.1177/01455613211048978. Online ahead of print. ABSTRACT Significance Statement: Neurofibromas, derived from perineural cells, are usually benign in the nervous system. Although neurofibromas are common in the head and neck, they rarely affect the external auditory canal (EAC), and few cases have been reported. We describe a case of a solitary EAC neurofibroma with otoscopy, radiological imaging, a surgical approa ch, and an uneventful outcome. PMID:34601890 | DOI:10.1177/01455613211048978 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Resolvin D2 suppresses NLRP3 inflammasome by promoting autophagy in macrophages

xlomafota13 shared this article with you from Inoreader Resolvin D2 suppresses NLRP3 inflammasome by promoting autophagy in macrophages Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1222. doi: 10.3892/etm.2021.10656. Epub 2021 Aug 26. ABSTRACT Inflammasome, a multiprotein complex that regulates interleukin (IL)-1β secretion and pyroptosis, participates in numerous inflammatory diseases, including sepsis, atherosclerosis and type-2 diabetes. Investigating the inflammasome regulation is therefore crucial to understand the inflammasome activation and develop treatment for the related diseases. In addition, it remains unknown how the inflammasome is naturally suppressed during the inflammatory process. The present study aimed to investigate the role of resolvin D2 (RvD2), an innate suppressor of inflammation produced from essential ω3-polyunsaturated fatty acids, in the activation of the inflammasome via in vitro and in vivo experiments. The effects of RvD2 on the cytokine production of inflammasome-related peritonitis were determined, and the NLRP3 inflammasome activation was investigated in the presence of RvD2. Moreover, the potential mechanisms underlying RvD2 in NLRP3 inflammasome regulation through autophagy and proteasome were investigated. The results of the present study demonstrated that RvD2 suppressed inflammasome-mediated peritonitis in vivo and regulated the NLR family pyrin domain containing 3 (NLRP3) inflammasome, but not in absent in melanoma 2 (AIM2), NLR family CARD domain containing 4 (NLRC4) inflammasomes. Mechanistically, RvD2 was found to promote the degradation of NLRP3 through autophagy, and the inhibition of autophagy could reverse the RvD2-mediated suppression of NLRP3 inflammasome in vitro and partially reverse the inflammasome-mediated peritonitis in vivo. In summary, the present study reported the negative regulation of NLRP3 inflammasome activation by RvD2. The findings from this study may extend the knowledge of the innate regulation of inflammasome and highlight a possible target for inflammasome-r elated diseases. PMID:34603519 | PMC:PMC8453332 | DOI:10.3892/etm.2021.10656 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Resolvin D2 suppresses NLRP3 inflammasome by promoting autophagy in macrophages

xlomafota13 shared this article with you from Inoreader Resolvin D2 suppresses NLRP3 inflammasome by promoting autophagy in macrophages Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1222. doi: 10.3892/etm.2021.10656. Epub 2021 Aug 26. ABSTRACT Inflammasome, a multiprotein complex that regulates interleukin (IL)-1β secretion and pyroptosis, participates in numerous inflammatory diseases, including sepsis, atherosclerosis and type-2 diabetes. Investigating the inflammasome regulation is therefore crucial to understand the inflammasome activation and develop treatment for the related diseases. In addition, it remains unknown how the inflammasome is naturally suppressed during the inflammatory process. The present study aimed to investigate the role of resolvin D2 (RvD2), an innate suppressor of inflammation produced from essential ω3-polyunsaturated fatty acids, in the activation of the inflammasome via in vitro and in vivo experiments. The effects of RvD2 on the cytokine production of inflammasome-related peritonitis were determined, and the NLRP3 inflammasome activation was investigated in the presence of RvD2. Moreover, the potential mechanisms underlying RvD2 in NLRP3 inflammasome regulation through autophagy and proteasome were investigated. The results of the present study demonstrated that RvD2 suppressed inflammasome-mediated peritonitis in vivo and regulated the NLR family pyrin domain containing 3 (NLRP3) inflammasome, but not in absent in melanoma 2 (AIM2), NLR family CARD domain containing 4 (NLRC4) inflammasomes. Mechanistically, RvD2 was found to promote the degradation of NLRP3 through autophagy, and the inhibition of autophagy could reverse the RvD2-mediated suppression of NLRP3 inflammasome in vitro and partially reverse the inflammasome-mediated peritonitis in vivo. In summary, the present study reported the negative regulation of NLRP3 inflammasome activation by RvD2. The findings from this study may extend the knowledge of the innate regulation of inflammasome and highlight a possible target for inflammasome-r elated diseases. PMID:34603519 | PMC:PMC8453332 | DOI:10.3892/etm.2021.10656 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

MicroRNA-92b promotes cell proliferation and invasion in osteosarcoma by directly targeting Dickkopf-related protein 3

xlomafota13 shared this article with you from Inoreader MicroRNA-92b promotes cell proliferation and invasion in osteosarcoma by directly targeting Dickkopf-related protein 3 Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1258. doi: 10.3892/etm.2021.10693. Epub 2021 Sep 3. ABSTRACT [This retracts the article DOI: 10.3892/etm.2017.5356.]. PMID:34603526 | PMC:PMC8453327 | DOI:10.3892/etm.2021.10693 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.